Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab”

107 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 107 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT07004335
What this trial is testing

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Who this might be right for
PD-(L)1CTLA-4Advanced Melanoma+3 more
Hebei Medical University Fourth Hospital 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07407452
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancers
Jiangsu Cancer Institute & Hospital 50
Post-approval studies (Phase 4)Not Yet RecruitingNCT07502027
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology 55
Testing effectiveness (Phase 2)Looking for participantsNCT07062055
What this trial is testing

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Who this might be right for
Hepatocellular CarcinomaPortal Vein Tumor ThrombusOligometastases+3 more
Shandong Cancer Hospital and Institute 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07045805
What this trial is testing

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Who this might be right for
Gastric Cancer (GC)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 66
Testing effectiveness (Phase 2)Looking for participantsNCT07530445
What this trial is testing

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Who this might be right for
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07413601
What this trial is testing

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 78
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07200947
What this trial is testing

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Who this might be right for
SMARCA4-Deficient TumorLocally Advanced or Metastatic Non-Small Cell Lung Cancer
Zhijie Wang 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07347444
What this trial is testing

Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma

Who this might be right for
Acral MelanomaMucosal Melanoma
Fudan University 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07172217
What this trial is testing

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

Who this might be right for
Recurrent Cervical Cancer
Qilu Hospital of Shandong University 33
Testing effectiveness (Phase 2)Looking for participantsNCT07099274
What this trial is testing

Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)Looking for participantsNCT07038629
What this trial is testing

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Who this might be right for
Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07400315
What this trial is testing

First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07009145
What this trial is testing

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Who this might be right for
Unresectable Colorectal CancerMetastatic Colorectal Cancer (CRC)MSI-H/dMMR Colorectal Cancer
Qianfoshan Hospital 22
Testing effectiveness (Phase 2)Looking for participantsNCT06908382
What this trial is testing

Neoadjuvant QL1706 Therapy for ESCC

Who this might be right for
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Shandong Provincial Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07315035
What this trial is testing

QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer

Who this might be right for
Gastric Cancer Stage III
The First Affiliated Hospital with Nanjing Medical University 74
Not applicableNot Yet RecruitingNCT07186868
What this trial is testing

QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer

Who this might be right for
Recurrent Cervical CancerMetastatic Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07286942
What this trial is testing

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

Who this might be right for
NSCLCNSCLC (Non-small Cell Lung Cancer)
Jiangsu Cancer Institute & Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT07315854
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital 32
Testing effectiveness (Phase 2)Looking for participantsNCT07070700
What this trial is testing

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)
Fudan University 56
Load More Results